Table 2.
Summary of ongoing phase 3 trials of immunotherapy combined with chemoradiotherapy for small cell lung cancer (ClinicalTrials.gov, accessed on 27 April 2021).
| NCT Number | Trial | Stage | Medication | Treatment |
|---|---|---|---|---|
| NCT03811002 | NRG-LU005 | LS | Atezolizumab Placebo |
CRT |
| NCT04402788 | NRG-LU007 RAPTOR |
ES | Atezolizumab | RT Obs. |
| NCT04624204 | MK 7339-013 KEYLYNK-013 |
LS | Pembrolizumab + Olaparib | CRT + PCI |
| NCT03703297 | ADRIATIC | LS | Durvalumab + Tremelimumab | CRT |
Abbreviations: LS, limited-stage; ES, extensive stage; CRT, chemoradiotherapy; Obs., observation; PCI, prophylactic cranial irradiation.